FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3000608434> ?p ?o ?g. }

• W3000608434 endingPage "2368" @default.
• W3000608434 startingPage "2362" @default.
• W3000608434 abstract "Objective High heparin doses during cardiopulmonary bypass (CPB) have been suggested to reduce thrombin activation and consumption coagulopathy and consequently bleeding complications. The authors investigated the effect of a high heparin dose during CPB on point-of-care measurements of coagulation. The authors hypothesized that during CPB a high heparin dose compared with a lower heparin dose would reduce thrombin generation and platelet activation and tested whether this would be reflected in the results of rotational thromboelastometry (TEM) and platelet aggregation, measured with multiple electrode aggregometry (MEA). Design Prospective, randomized, controlled, open single-center study. Setting University teaching hospital. Participants Sixty-three consecutive patients undergoing elective coronary artery bypass grafting with CPB were enrolled. Interventions Patients were randomly assigned to receive either a high (600 IU/kg, n = 32) or a low (300 IU/kg, n = 31) initial dose of heparin. Target levels of activated clotting time during CPB were >600 seconds in the high heparin dose group and >400 seconds in the low heparin dose group. Measurements and Main Results Blood samples were collected (1) preoperatively after induction of anesthesia, (2) 10 minutes after aortic declamping, (3) 30 minutes after protamine administration, and (4) 3 hours after protamine administration. TEM and MEA were then measured. There was no difference in blood loss up to 18 hours postoperatively (median 735 mL for high dose v 610 mL for low dose; p < 0.056) or transfusions between the groups. Total median heparin dose (54,300 IU v 27,000 IU; p = 0.001) and median antifactor Xa levels during CPB (9.38 U/mL v 5.04 U/mL; p = 0.001) were greater in the high than in the low heparin dose group. However, neither TEM nor MEA results differed significantly between the groups. Conclusions Compared with a lower dose of heparin during CPB, a high dose of heparin had little effect on the point-of-care measurements of hemostasis, TEM, and MEA. Based on the similarity of platelet and coagulation activity assessments, the higher heparin dose does not appear to offer benefit during CPB. High heparin doses during cardiopulmonary bypass (CPB) have been suggested to reduce thrombin activation and consumption coagulopathy and consequently bleeding complications. The authors investigated the effect of a high heparin dose during CPB on point-of-care measurements of coagulation. The authors hypothesized that during CPB a high heparin dose compared with a lower heparin dose would reduce thrombin generation and platelet activation and tested whether this would be reflected in the results of rotational thromboelastometry (TEM) and platelet aggregation, measured with multiple electrode aggregometry (MEA). Prospective, randomized, controlled, open single-center study. University teaching hospital. Sixty-three consecutive patients undergoing elective coronary artery bypass grafting with CPB were enrolled. Patients were randomly assigned to receive either a high (600 IU/kg, n = 32) or a low (300 IU/kg, n = 31) initial dose of heparin. Target levels of activated clotting time during CPB were >600 seconds in the high heparin dose group and >400 seconds in the low heparin dose group. Blood samples were collected (1) preoperatively after induction of anesthesia, (2) 10 minutes after aortic declamping, (3) 30 minutes after protamine administration, and (4) 3 hours after protamine administration. TEM and MEA were then measured. There was no difference in blood loss up to 18 hours postoperatively (median 735 mL for high dose v 610 mL for low dose; p < 0.056) or transfusions between the groups. Total median heparin dose (54,300 IU v 27,000 IU; p = 0.001) and median antifactor Xa levels during CPB (9.38 U/mL v 5.04 U/mL; p = 0.001) were greater in the high than in the low heparin dose group. However, neither TEM nor MEA results differed significantly between the groups. Compared with a lower dose of heparin during CPB, a high dose of heparin had little effect on the point-of-care measurements of hemostasis, TEM, and MEA. Based on the similarity of platelet and coagulation activity assessments, the higher heparin dose does not appear to offer benefit during CPB." @default.
• W3000608434 created "2020-01-23" @default.
• W3000608434 creator A5007865127 @default.
• W3000608434 creator A5020210319 @default.
• W3000608434 creator A5049688713 @default.
• W3000608434 creator A5051498958 @default.
• W3000608434 creator A5055770780 @default.
• W3000608434 creator A5080648467 @default.
• W3000608434 date "2020-09-01" @default.
• W3000608434 modified "2023-09-26" @default.
• W3000608434 title "Heparin Dose and Point-of-Care Measurements of Hemostasis in Cardiac Surgery—Results of a Randomized Controlled Trial" @default.
• W3000608434 cites W1501810766 @default.
• W3000608434 cites W1591788256 @default.
• W3000608434 cites W1969642529 @default.
• W3000608434 cites W1971253813 @default.
• W3000608434 cites W1998509878 @default.
• W3000608434 cites W2000865193 @default.
• W3000608434 cites W2003800825 @default.
• W3000608434 cites W2028312716 @default.
• W3000608434 cites W2029970434 @default.
• W3000608434 cites W2043969800 @default.
• W3000608434 cites W2051207467 @default.
• W3000608434 cites W2084206146 @default.
• W3000608434 cites W2103047609 @default.
• W3000608434 cites W2107355941 @default.
• W3000608434 cites W2109584708 @default.
• W3000608434 cites W2111773029 @default.
• W3000608434 cites W2113649772 @default.
• W3000608434 cites W2134477676 @default.
• W3000608434 cites W2135344285 @default.
• W3000608434 cites W2150901988 @default.
• W3000608434 cites W2162928891 @default.
• W3000608434 cites W2167739859 @default.
• W3000608434 cites W2168940093 @default.
• W3000608434 cites W2179531171 @default.
• W3000608434 cites W2378984699 @default.
• W3000608434 cites W2775038098 @default.
• W3000608434 cites W2783757138 @default.
• W3000608434 cites W30189465 @default.
• W3000608434 doi "https://doi.org/10.1053/j.jvca.2019.12.050" @default.
• W3000608434 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32127275" @default.
• W3000608434 hasPublicationYear "2020" @default.
• W3000608434 type Work @default.
• W3000608434 sameAs 3000608434 @default.
• W3000608434 citedByCount "7" @default.
• W3000608434 countsByYear W30006084342020 @default.
• W3000608434 countsByYear W30006084342021 @default.
• W3000608434 countsByYear W30006084342022 @default.
• W3000608434 countsByYear W30006084342023 @default.
• W3000608434 crossrefType "journal-article" @default.
• W3000608434 hasAuthorship W3000608434A5007865127 @default.
• W3000608434 hasAuthorship W3000608434A5020210319 @default.
• W3000608434 hasAuthorship W3000608434A5049688713 @default.
• W3000608434 hasAuthorship W3000608434A5051498958 @default.
• W3000608434 hasAuthorship W3000608434A5055770780 @default.
• W3000608434 hasAuthorship W3000608434A5080648467 @default.
• W3000608434 hasBestOaLocation W30006084342 @default.
• W3000608434 hasConcept C141071460 @default.
• W3000608434 hasConcept C168563851 @default.
• W3000608434 hasConcept C26809991 @default.
• W3000608434 hasConcept C2777557582 @default.
• W3000608434 hasConcept C2777987278 @default.
• W3000608434 hasConcept C2778205648 @default.
• W3000608434 hasConcept C2778589496 @default.
• W3000608434 hasConcept C2778789114 @default.
• W3000608434 hasConcept C2778881276 @default.
• W3000608434 hasConcept C2779936836 @default.
• W3000608434 hasConcept C2780835560 @default.
• W3000608434 hasConcept C42219234 @default.
• W3000608434 hasConcept C71924100 @default.
• W3000608434 hasConceptScore W3000608434C141071460 @default.
• W3000608434 hasConceptScore W3000608434C168563851 @default.
• W3000608434 hasConceptScore W3000608434C26809991 @default.
• W3000608434 hasConceptScore W3000608434C2777557582 @default.
• W3000608434 hasConceptScore W3000608434C2777987278 @default.
• W3000608434 hasConceptScore W3000608434C2778205648 @default.
• W3000608434 hasConceptScore W3000608434C2778589496 @default.
• W3000608434 hasConceptScore W3000608434C2778789114 @default.
• W3000608434 hasConceptScore W3000608434C2778881276 @default.
• W3000608434 hasConceptScore W3000608434C2779936836 @default.
• W3000608434 hasConceptScore W3000608434C2780835560 @default.
• W3000608434 hasConceptScore W3000608434C42219234 @default.
• W3000608434 hasConceptScore W3000608434C71924100 @default.
• W3000608434 hasIssue "9" @default.
• W3000608434 hasLocation W30006084341 @default.
• W3000608434 hasLocation W30006084342 @default.
• W3000608434 hasOpenAccess W3000608434 @default.
• W3000608434 hasPrimaryLocation W30006084341 @default.
• W3000608434 hasRelatedWork W1979053501 @default.
• W3000608434 hasRelatedWork W2003963773 @default.
• W3000608434 hasRelatedWork W2029364688 @default.
• W3000608434 hasRelatedWork W206436102 @default.
• W3000608434 hasRelatedWork W2079160576 @default.
• W3000608434 hasRelatedWork W2333224211 @default.
• W3000608434 hasRelatedWork W2416007221 @default.
• W3000608434 hasRelatedWork W2577735013 @default.
• W3000608434 hasRelatedWork W3155730258 @default.
• W3000608434 hasRelatedWork W816451784 @default.

• next